Alerta

DENDRIMER NANOPARTICLES FOR TREATING KIDNEY DISEASES AND METHODS OF USE THEREOF

Resumen de: WO2026183193A1

Disclosed are nanoparticles and compositions thereof for delivering active agents to the kidney. The nanoparticles include a dendrimer, a targeting ligand, and one or more active agents. From 5% to less than 90% of the dendrimer's surface groups can be modified with one or more functional groups e.g., acetyl groups. The dendrimer can be a PAMAM dendrimer or a saccharide dendrimer. The targeting ligand, such as folic acid, is conjugated to unmodified surface groups. Active agents, including small molecules (e.g., PPAR-α agonists), peptides, or nucleic acids, are encapsulated or associated with the nanoparticles. The nanoparticles have a neutral or positive zeta potential, ranging from about 0 mV to about 30 mV, and a diameter of ranging from 1 to 30 nm. Also disclosed are methods of administering the nanoparticle compositions for treating kidney diseases in a subject in need thereof.

ULTRA-SMALL METALLIC NANOPARTICLES

Resumen de: WO2026181080A1

Metal nanoparticles comprising at least one metal atom and a ligand associated with at least a portion of a surface of the metal atom, and uses thereof, are provided. The ligand is made of a first moiety (denoted as X) that is capable of associating with the surface of the metal atom; and an additional moiety (denoted as Y) which is a redox-reactive moiety and/or a second moiety that is capable of associating with the surface of the metal atoms, and optionally a linking moiety that links the first moiety and the additional moiety. The metal nanoparticles are ultra-small nanoparticles. The metal nanoparticles are usable in, for example, catalyzing redox reactions and as coatings for varying surfaces, and are capable of interacting with a myriad of substances, such as liposomes and oligonucleotides, rendering these nanoparticles usable in varying applications.

NANOPARTICLE IMMUNOSUPPRESSANT FOR RETINAL APPLICATIONS

Resumen de: WO2026183437A1

Provided herein are pharmaceutical compositions that include (a) a dendrimer nanoparticle, wherein the dendrimer nanoparticle comprises Dexamethasone-21-succinate, and (b) a plurality of retinal cells. Also provided herein are methods for treating a degenerative and hereditary retinopathy that include administering any one of the pharmaceutical compositions described herein to a subject in need thereof.

CUPROPTOSIS-DRIVEN NANORADIOTHERAGNOSTICS FOR CANCER

Resumen de: WO2026183342A1

The present technology relates generally to nanoparticles including bovine serum albumin and a first copper complex including diethyldithiocarbamate and Cu2+, and optionally including a second copper complex including diethyldithiocarbamate and 64Cu2+, and optionally including a third copper complex including diethyldithiocarbamate and 67Cu2+ for treating, imaging, and/or detecting a cancer.

LIPID NANOPARTICLES FOR INDUCING TOLERANCE IN HUMAN CELLS

Resumen de: WO2026180744A1

The invention provides a lipid composition or LNP comprising (i) one or more cationic ionizable lipids and, optionally, one or more permanent cationic lipids, (ii) one or more phospholipids, (iii) one or more amphiphilic compounds comprising a hydrophilic polymer chain having one or more hydrophobic groups, (iv) optionally cholesterol or a cholesterol ester, (v) a lipophilic agent other than cholesterol and a cholesterol ester, and (vi) one or more polynucleotide(s).

Nanocarrier Composition with Adjustable Structure, Preparation Method and Use Thereof

Resumen de: US20260256942A1

The present disclosure discloses a nanocarrier composition with adjustable structure, preparation method and use thereof. The nanocarrier composition is prepared by adding a regulator to lecithin. By adding different types of regulators, the nanocarrier composition can be converted between a liposome structure or a micelle structure. When applied to medical purposes, under the same nanocarrier composition preparation process, under the same nanocarrier composition manufacturing process, the structure of the nanocarrier composition can be changed by simply changing the type of added regulator, thereby controlling the drug release time, drug penetration and bioavailability. The nanocarrier composition can be converted into a suitable structure to facilitate drug delivery according to the requirements of different dosage forms.

NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME

Resumen de: WO2025090663A1

The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.

ENCAPSULATED COMPOSITIONS FOR DENTAL AND BONE REMINERALISATION

Resumen de: EP4799601A1

0001 The present invention relates to the field of medicinal tissue mineralisation, in particular, i.e. tooth remineralisation and bone regeneration with self-assembling peptides. Use of self-assembling peptides, such as P11-4, also designated Oligopeptide-104, in these processes leads to generation of hydroxyapatite, which is also present in natural enamel, dentin and bone. The inventors have discovered that this can be significantly accelerated by combining a self-assembling peptide (SAP) such as P11-4, calcium ions, phosphate ions, and a polymer in the form of particles encapsulating a cargo selected from at least one of the SAP, the calcium ions and the phosphate ions into a composition or kit. The invention also provides medical use of said composition or kit, in particular, in the tooth, for remineralisation of caries lesions, such as subsurface caries lesions, mineralisation of pits and fissures, treatment of sensitive teeth, pulp capping, and for bone regeneration.

分岐頭基を有するイオン化可能な脂質

Resumen de: US20260176252A1

0000 The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use such as a compound of Formula (A) or a pharmaceutically acceptable salt thereof. 0000

BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: WO2025090417A1

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

NANOPARTICLE BASED DELIVERY OF MITOCHONDRIAL DNA (MTDNA) AND METHODS OF USE THEREOF

Resumen de: WO2025090891A1

In some embodiments, the invention relates to a composition for targeted delivery of intact mitochondrial DNA (mtDNA) to a target cell, the composition comprising a mtDNA molecule that is complexed to cell-penetrating peptides (CPPs) which promote cellular entry, wherein the complex forms a nanoparticle with the CPPs bound to the mtDNA molecule. In some embodiments, the invention relates to a method of treating a disease or disorder associated with mitochondrial dysfunction in a subject in need thereof.

ALGA(E) NANOPARTICLES AND USES THEREOF FOR DRUG DELIVERY

Resumen de: WO2025088609A1

Disclosed are biocompatible, biodegradable, and low immunogenic alga(e) Nanoparticles (aNPs) that can adhere and deliver active ingredient(s) to mucosal epithelium tissue, as well as compositions comprising the aNPs, methods of preparing the aNPs, and uses thereof in methods of treatment.

NANOPARTICLE COMPOSITION FOR DRUG DELIVERY

Resumen de: EP4799614A1

0001 The present invention relates to a composition for drug delivery and a preparation method therefor and, more specifically, to: a composition for drug delivery which is formed such that a drug is encapsulated inside a nanoparticle structure formed by a polymer and a cationic lipid having a specific structure; and a preparation method therefor.

IMMUNOLOGIC ADJUVANT COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: EP4799638A1

Provided are an immunological adjuvant composition, a preparation method and use thereof. The immunological adjuvant composition comprises an immune activator and a liposome for loading the immune activator, wherein the immune activator includes a saponin and a CpG oligodeoxynucleotide. The immunological adjuvant composition is capable of eliciting an immune response against human herpesvirus and/or hepatitis B virus in a mammal and inducing a strong level of cellular immune response. By using the liposome to simultaneously load QS21 and the CpG oligodeoxynucleotide, the two components exhibit a favorable synergistic effect in promoting cellular immunity, and can induce a stronger level of cellular immune response compared to the commercially available vaccine Shingrix.

ABCB5-TARGETED STEM CELL REPROGRAMMING AND ANTI-AGING STRATEGIES

Resumen de: WO2025090565A1

Methods and compositions for rejuvenating and reprogramming stem cells are disclosed. The methods involve administering to a subject an ABCB5 targeted composition comprising an anti-ABCB5 antibody conjugated to a therapeutic payload comprised of an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor in an effective amount to reprogram and rejuvenate ABCB5+ stem cells in the subject. The compositions include anti-ABCB5 antibody conjugated to a therapeutic payload comprising an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor.

COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Resumen de: EP4799694A2

The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.

METHODS FOR THE COUPLING OF DI(ALKYL)AMINES TO POLYPEPTIDES

Resumen de: WO2025088192A1

The present invention provides for inventive means and methods for the coupling of di(alkyl)amines to polypeptides or peptides capable of forming a random coil conformation. The present invention further provides inventive compounds produced by the herein detailed methods, wherein said compounds are characterized by formula (I): A-B-bC-D. Said compounds comprise a polypeptide/peptide capable of forming a random coil conformation, an N-terminal protecting group, a di(alkyl)amino group, and optionally a linker. Furthermore, the present invention provides lipid nanoparticles comprising said compounds characterized by formula (I) as well as means and methods for the production of said lipid nanoparticles. Formulations comprising the inventive compounds and/or the lipid nanoparticles of the present invention are also provided. Further, the present invention also relates to uses of the inventive compounds, the lipid nanoparticles, and/or the formulations disclosed herein.

IONIZABLE LIPID AND USE THEREOF

Resumen de: EP4800017A1

0001 The present invention relates to a novel ionizable lipid compound represented by Formula (I), or a salt thereof, and lipid nanoparticles comprising same. The lipid nanoparticles comprising the novel ionizable lipid compound, according to the present invention, have excellent nucleic acid encapsulation efficiency and high nucleic acid cell delivery efficiency.

IONIZABLE LIPIDS AND USES THEREOF

Resumen de: WO2025089791A1

The present invention relates to a novel ionizable lipid compound represented by Formula (I) or a salt thereof, and a lipid nanoparticle containing the same. The lipid nanoparticle containing the novel ionizable lipid compound according to the present invention has an excellent nucleic acid encapsulation efficiency and has a high efficiency of cellular delivery of nucleic acid.

COMPOSITIONS AND METHODS FOR TARGETING LIPID NANOPARTICLES

Resumen de: WO2025085950A1

The present invention is directed to lipid-based nanoparticles (e.g. lipid nanoparticles), formulations containing lipid-based nanoparticles and methods of treating diseases or conditions with said lipid-based nanoparticles and formulations thereof. The present invention provides a lipid-based nanoparticle comprising (a) an active agent, and (b) a plurality of capture binding domains displayed on the outer surface of the nanoparticle, wherein each capture binding domain is linked to the lipid-based nanoparticle through a site-specific linkage such that each capture binding domain is displayed in substantially the same orientation and capable of capturing a targeting moiety in an orientation that allows the targeting moiety to interact with its target. The present invention also provides a lipid-based nanoparticle comprising (a) an active agent, and (b) a plurality of targeting molecules displayed on the outer surface of the nanoparticle, wherein each targeting molecule is linked to the lipid-based nanoparticle through a site-specific linkage such that each targeting molecule is displayed in substantially the same orientation and capable of binding to a target on a cell surface.

STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: WO2025090138A1

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, hematopoietic stem cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

一种纳米颗粒及其制备方法和应用

Resumen de: CN122664963A

本发明属于医药技术领域，尤其涉及一种纳米颗粒及其制备方法和应用。本发明纳米颗粒的制备方法，包括以下步骤：称取COOH‑PEG‑PLGA、NHS、EDC和N,N‑二异丙基乙胺加入DMF中，活化COOH‑PEG‑PLGA，然后加入缀合物进行反应，得到改性PEG‑PLGA；将改性PEG‑PLGA、金丝桃苷和茵芋碱加入丙酮中，配制成油相溶液；将聚乙烯醇加入蒸馏水中，配制成水相溶液；将油相溶液加入水相溶液中，乳化得纳米颗粒。该纳米颗粒以改性PEG‑PLGA为载体，有效提高了金丝桃苷的包载率和心肌细胞靶向性。金丝桃苷与茵芋碱二者联用能够减少心肌缺血区域面积，降低心肌纤维化程度，并改善心功能。

一种纳米颗粒和包含纳米颗粒的囊泡递送系统及其制备方法和应用

Resumen de: CN122664962A

本发明属于生物医药技术领域，公开了一种纳米颗粒和包含纳米颗粒的囊泡递送系统及其制备方法和应用。所述纳米颗粒包括核心及包覆于核心表面的壳层；核心包括具有抗氧化活性的纳米酶，壳层包括多肽。所述囊泡递送系统包括细胞外囊泡和封装于所述细胞外囊泡内部的所述纳米颗粒。可选地，纳米颗粒还可包括包覆于壳层表面的多糖外壳层。本发明提供的纳米颗粒及囊泡递送系统能高效清除活性氧、恢复线粒体功能、逆转髓核细胞应激性衰老，并经体内外实验验证具有显著的抗炎、抗氧化、抗衰老及修复椎间盘结构的效果。

一种水溶性丝素蛋白富勒烯复合物及其制备方法和应用

Resumen de: CN122664868A

本发明涉及一种水溶性丝素蛋白富勒烯复合物及其制备方法和应用，属于富勒烯改性技术领域，用于解决现有的富勒烯改性方法多采用化学表面活性剂，生物安全性差；改性富勒烯的增殖作用弱、高温稳定性差的问题。包括以下步骤：将富勒烯、丝素蛋白和弱碱性助剂混合，进行球磨，得到第一混合粉体；向第一混合粉体中加入过氧化氢溶液，继续球磨，得到第二混合物料；向第二混合物料中加入水，经超声微流体均质机处理，得到悬浊液；将悬浊液离心，收集上层清液；将上层清液进行透析纯化，得到水溶性丝素蛋白富勒烯复合物水溶液。本发明的水溶性丝素蛋白富勒烯复合物水溶性好，有良好的生物安全性和抗氧化性，有良好的增殖作用和稳定性。

一种靶向三阴性乳腺癌的核壳结构仿生纳米药物及其制备方法和应用

Nº publicación: CN122664958A 01/09/2026

Solicitante:

安徽医科大学

Resumen de: CN122664958A

本发明属于生物医药，具体涉一种靶向三阴性乳腺癌的核壳结构仿生纳米药物及其应用；本发明构建了一种核壳结构的仿生纳米药物递送系统AMT NPs，其以DNA四面体为内核、RAET杂化膜为外壳。该核壳结构平台通过RAET涂层与DNA四面体内核的协同整合，在激活抗肿瘤免疫应答的同时克服耐药性，并降低了载体自身的生物毒性，从而同时解决三阴性乳腺癌治疗中免疫原性缺失、免疫抑制微环境及多药耐药三大关键挑战，为精准癌症免疫治疗提供了新策略。